A heparanase-specific LYTAC degrader reinforces natural killer cell cytotoxicity within the tumor microenvironment
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Immune Cell Function and Interaction · CAR-T cell therapy research · Immunotherapy and Immune Responses
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (47)
Show source-provided references
1. Immunotherapies for hepatocellular carcinoma10.1038/s41571-021-00573-2 ↗
2. Cancer incidence, mortality, and burden in China: a time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 202010.1002/cac2.12197 ↗
3. Natural killer cell dysfunction in hepatocellular carcinoma and NK cell-based immunotherapy10.1038/aps.2015.41 ↗
4. Liver: An organ with predominant innate immunity10.1002/hep.22034 ↗
5. The biology of human natural killer-cell subsets10.1016/S1471-4906(01)02060-9 ↗
6. Targeting natural killer cells in cancer immunotherapy10.1038/ni.3518 ↗
7. Designing Cancer Immunotherapies That Engage T Cells and NK Cells10.1146/annurev-immunol-101921-044122 ↗
8. Combination of NK-based immunotherapy and sorafenib against hepatocellular carcinoma
9. Advances in immunotherapy for hepatocellular carcinoma10.1038/s41575-021-00438-0 ↗
10. The NK cell-cancer cycle: advances and new challenges in NK cell-based immunotherapies10.1038/s41590-020-0728-z ↗
11. NK cells for cancer immunotherapy10.1038/s41573-019-0052-1 ↗
12. NK cell-based immunotherapy for malignant diseases10.1038/cmi.2013.10 ↗
13. Human NK cells: surface receptors, inhibitory checkpoints, and translational applications10.1038/s41423-019-0206-4 ↗
14. The cancer-natural killer cell immunity cycle10.1038/s41568-020-0272-z ↗
15. Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma10.1182/blood-2006-08-043232 ↗
16. MicroRNA-1258 suppresses breast cancer brain metastasis by targeting heparanase10.1158/0008-5472.CAN-10-1910 ↗
17. miRNA-558 promotes gastric cancer progression through attenuating Smad4-mediated repression of heparanase expression10.1038/cddis.2016.293 ↗
18. Regulation of ligands for the NKG2D activating receptor10.1146/annurev-immunol-032712-095951 ↗
19. Roles of heparan-sulphate glycosaminoglycans in cancer10.1038/nrc842 ↗
20. Function from within: Autophagy induction by HPSE/heparanase--new possibilities for intervention10.1080/15548627.2015.1115174 ↗
21. Heparanase induces necroptosis of microvascular endothelial cells to promote the metastasis of hepatocellular carcinoma10.1038/s41420-021-00411-5 ↗
22. Heparanase-1 is upregulated by hepatitis C virus and favors its replication10.1016/j.jhep.2022.01.008 ↗
23. Modulation of the heparanase-inhibiting activity of heparin through selective desulfation, graded N-acetylation, and glycol splitting10.1074/jbc.M414217200 ↗
24. PI-88 and novel heparan sulfate mimetics inhibit angiogenesis10.1055/s-2007-982088 ↗
25. Suppression of endoplasmic reticulum stress-induced invasion and migration of breast cancer cells through the downregulation of heparanase10.3892/ijmm.2013.1292 ↗
26. Heparanase: A Challenging Cancer Drug Target10.3389/fonc.2019.01316 ↗
27. LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation10.1038/s41589-021-00770-1 ↗
28. Elucidating the cellular determinants of targeted membrane protein degradation by lysosome-targeting chimeras10.1126/science.adf6249 ↗
29. Lysosome-targeting chimaeras for degradation of extracellular proteins10.1038/s41586-020-2545-9 ↗
30. Degradation from the outside in: Targeting extracellular and membrane proteins for degradation through the endolysosomal pathway10.1016/j.chembiol.2021.02.024 ↗
31. Recent advances in the development of EGFR degraders: PROTACs and LYTACs10.1016/j.ejmech.2022.114533 ↗
32. Nano-LYTACs for Degradation of Membrane Proteins and Inhibition of CD24/Siglec-10 Signaling Pathway
33. Development of Triantennary N-Acetylgalactosamine Conjugates as Degraders for Extracellular Proteins10.1021/acscentsci.1c00146 ↗
34. Bifunctional small molecules that mediate the degradation of extracellular proteins10.1038/s41589-021-00851-1 ↗
35. Aptamer-LYTACs for Targeted Degradation of Extracellular and Membrane Proteins
36. Covalent LYTAC Enabled by DNA Aptamers for Immune Checkpoint Degradation Therapy
37. Clearance of plasma PCSK9 via the asialoglycoprotein receptor mediated by heterobifunctional ligands10.1016/j.chembiol.2022.12.003 ↗
38. Furanyl-1,3-thiazol-2-yl and benzoxazol-5-yl acetic acid derivatives: novel classes of heparanase inhibitor10.1016/j.bmcl.2005.03.014 ↗
39. BPTF inhibits NK cell activity and the abundance of natural cytotoxicity receptor co-ligands10.18632/oncotarget.17834 ↗
40. The asialoglycoprotein receptor: a model for endocytic transport receptors10.1021/bi00495a001 ↗
41. Inhibition of hepatocarcinoma by systemic delivery of Apoptin gene via the hepatic asialoglycoprotein receptor10.1038/sj.cgt.7700985 ↗
42. Inactivation of Wnt signaling by a human antibody that recognizes the heparan sulfate chains of glypican-3 for liver cancer therapy10.1002/hep.26996 ↗
43. Interactions between driver genes shape the signaling pathway landscape and direct hepatocellular carcinoma therapy10.1111/cas.15788 ↗
44. Targeting Lysosomal Degradation Pathways: New Strategies and Techniques for Drug Discovery10.1021/acs.jmedchem.0c01689 ↗
45. Semiconducting Polymer Nanoparticles with Surface-Mimicking Protein Secondary Structure as Lysosome-Targeting Chimaeras for Self-Synergistic Cancer Immunotherapy10.1002/adma.202203309 ↗
46. ROTACs leverage signaling-incompetent R-spondin for targeted protein degradation10.1016/j.chembiol.2023.05.010 ↗
47. Biomarker-activated multifunctional lysosome-targeting chimeras mediated selective degradation of extracellular amyloid fibrils10.1016/j.chempr.2023.06.003 ↗